Literature DB >> 26869671

Inflammatory bowel disease and risk of mortality in COPD.

Maria Vutcovici1, Alain Bitton2, Pierre Ernst3, Abbas Kezouh4, Samy Suissa3, Paul Brassard5.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) have higher incidence and prevalence of other chronic inflammatory diseases, including inflammatory bowel disease (IBD). We assessed whether IBD onset increases mortality risk in patients with COPD or asthma-associated COPD.Two population-based cohorts of COPD and asthma-COPD subjects were identified using the administrative health databases in Québec, Canada, 1990-2007. Death records were retrieved from the death certificate registry. Cox proportional hazards models were used to assess the impact of newly developed IBD on mortality risk.The COPD and asthma-COPD cohorts included 273 208 and 26 575 patients, respectively, of which 697 and 119 developed IBD. IBD increased the risk of all-cause mortality in both COPD (hazard ratio 1.23, 95% CI 1.09-1.4) and asthma-COPD (hazard ratio 1.65, 95% CI 1.23-2.22). In asthma-COPD patients, IBD increased the risk of mortality from respiratory conditions (hazard ratio 2.18, 95% CI 1.31-3.64); in COPD patients, IBD increased the risk of death from digestive conditions (hazard ratio 4.45, 95% CI 2.39-8.30).IBD is a risk factor for mortality in patients with pre-existing COPD or asthma-COPD. IBD increased mortality by respiratory and digestive conditions in patients with asthma-COPD and COPD, respectively.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 26869671     DOI: 10.1183/13993003.01945-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Gut-lung Microbiota Interactions in Chronic Obstructive Pulmonary Disease (COPD): Potential Mechanisms Driving Progression to COPD and Epidemiological Data.

Authors:  Francesco De Nuccio; Prisco Piscitelli; Domenico Maurizio Toraldo
Journal:  Lung       Date:  2022-10-14       Impact factor: 3.777

2.  Emerging trends and hotspot in gut-lung axis research from 2011 to 2021: a bibliometrics analysis.

Authors:  Zhendong Wang; Chen Bai; Tingyao Hu; Changyong Luo; He Yu; Xueyan Ma; Tiegang Liu; Xiaohong Gu
Journal:  Biomed Eng Online       Date:  2022-04-21       Impact factor: 3.903

3.  Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review.

Authors:  Arnold N Forlemu; Raissa Nana Sede Mbakop; Shehroz Aslam; Zaid Ansari; Indu Srinivasan; Keng-Yu Chuang
Journal:  Cureus       Date:  2022-08-02

4.  Walking exercise alters protein digestion, amino acid absorption, and whole body protein kinetics in older adults with and without COPD.

Authors:  Clayton L Cruthirds; Nicolaas E P Deutz; Gerdien C Ligthart-Melis; Sunday Y Simbo; Mariëlle P K J Engelen
Journal:  J Appl Physiol (1985)       Date:  2020-11-19

Review 5.  Inflammatory bowel disease and airway diseases.

Authors:  Maria Vutcovici; Paul Brassard; Alain Bitton
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

6.  Association between inflammatory bowel disease and chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Gonzalo Labarca; Lauren Drake; Gloria Horta; Michael A Jantz; Hiren J Mehta; Sebastian Fernandez-Bussy; Erik Folch; Adnan Majid; Michael Picco
Journal:  BMC Pulm Med       Date:  2019-10-28       Impact factor: 3.317

7.  Ebselen prevents cigarette smoke-induced gastrointestinal dysfunction in mice.

Authors:  Ross Vlahos; Elisa L Hill-Yardin; Gayathri K Balasuriya; Mitra Mohsenipour; Kurt Brassington; Aleksandar Dobric; Simone N De Luca; Kevin Mou; Huei Jiunn Seow; Chalystha Yie Qin Lee; Madushani Herath; Stanley M H Chan
Journal:  Clin Sci (Lond)       Date:  2020-11-27       Impact factor: 6.124

Review 8.  Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.

Authors:  April L Raftery; Evelyn Tsantikos; Nicola L Harris; Margaret L Hibbs
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.